Back to News
Market Impact: 0.3
ANI Offers $560 Mln To Acquire Egetis, Expand Rare Disease Business
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
ANI Pharmaceuticals announced a recommended cash offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million), including outstanding incentive programs. The article provides no offer premium, completion timetable, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
ANIP0.60
EGTX0.50
More News
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition
- Five9 falls 22% on disappointing fourth quarter EPS outlook
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Here's where we stand on Kimberly-Clark shares after a better-than-feared quarter
- SpaceX, Tesla extend losses as midterm results cloud data center, merger outlook
- Mattel cuts annual forecasts as new CEO takes charge